X0202 SCHEDULE 13G/A 0001172661-25-004947 0001583977 XXXXXXXX LIVE 1 Common Stock, $0.001 par value per share 03/31/2026 0001420720 iBio, Inc. 451033708 600 MADISON AVENUE SUITE 1601 NEW YORK NY 10022-1737 Rule 13d-1(b) Cormorant Asset Management, LP b DE 0.00 3834335.00 0.00 3834335.00 3834335.00 N 9.99 IA PN Bihua Chen b X1 0.00 3834335.00 0.00 3834335.00 3834335.00 N 9.99 HC IN iBio, Inc. 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121 Cormorant Asset Management, LP Bihua Chen This statement is filed by (i) Cormorant Asset Management, LP, a Delaware limited partnership, and the investment adviser to certain funds (the "Cormorant Funds"), with respect to the shares directly held by the Cormorant Funds and (ii) Bihua Chen with respect to the shares directly held by the Cormorant Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares reported herein. 200 Clarendon Street, 52nd Floor Boston, MA 02116 Cormorant Asset Management, LP - Delaware Bihua Chen - United States N IA HC 3,834,335 9.99% 0 3,834,335 0 3,834,335 The Reporting Persons' holdings reported herein reflect shares of common stock of the Issuer ("Common Stock") issuable upon the exercise of pre-funded warrants and/or Series G warrants (collectively, the "Warrants"); provided that the Warrants may not be exercised if such exercise would cause the holder, together with its affiliates, to beneficially own in excess of 9.99% of the number of shares of the Issuer's Common Stock then outstanding. The Warrants would be exercisable for up to 7,752,005 shares of Common Stock, subject to the limitation on exercise. If not for such limitation on exercise, the Reporting Persons would beneficially own in excess of 9.99% of the Issuer's Common Stock. The Reporting Persons' holdings reported herein does not include 3,570,000 shares of Common Stock issuable upon exercise of a Series H warrant that is issuable only upon the exercise of the Series G warrant. The percentages reported herein with respect to the Reporting Persons' holdings are calculated based upon a statement in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2025, as filed with the Securities and Exchange Commission on February 10, 2026, that there were 34,543,561 shares of Common Stock of the Issuer outstanding as of February 9, 2026. Y N See Item 2. The Cormorant Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares reported herein. Cormorant Global Healthcare Master Fund, LP, a Cormorant Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the shares. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Joint Filing Statement, incorporated by reference to the Joint Filing Statement included with the Schedule 13G filed by the Reporting Persons on November 14, 2025. Cormorant Asset Management, LP /s/ Bihua Chen 05/15/2026 Bihua Chen /s/ Bihua Chen 05/15/2026